These results suggest that a high EphA2 level is associated with increased survival in HER2-negative breast cancers and that EphA2 suppresses tumorigenesis and the tumor-suppressive function of EphA2 is augmented under low RNF5 expression in ER-positive HER2-negative breast cancers. Here, RNF5 is linked to breast carcinoma.